Hey AllI have no stock in ARX, I am heavily loaded in Polynovo-...

Hey All

I have no stock in ARX, I am heavily loaded in Polynovo- I saw the end of year results- well done to the company-
When I tried to raised ARX as a competitor to Polynovo (ruminant sheep product vs synthetic) a few numpties who think they own the PNV threads shouted down, saying stop fretting, that ARX isn't competition, ARX have no journal articles published. TBH, it showed these PNV investors were poorly informed.

Whats the investors here take on: Polynovo vs Aroa?
I see Aroa have 220 staff (40 sales staff just in US-33 field and 7 inside sales reps) vs Polynovo has 150 staff I believe or there abouts
Aroa generating 39.6 Million NZD revenue- they have 6 products commercialised and a larger TAM then Polynovo as a result of this.
Polynovo have 30.4 Million AUD revenue from 3 quarters, and I'm expecting about 44-45 million AUD for the year when results are out, 1 product commercialised but a couple more in the pipeline- for hernia, breast and also diabetic ulcers (I note ARX also have products in this space). Seems like PNV is generating about 48-49 million NZD with 150 staff (20% more revenue) but from 150 staff vs 220 staff (35% less staff than ARX) but only have one product.

But ARX market cap of 250 million, vs PNV market cap of 1 Billion, when you consider the annual revenue each are generating, may make ARX a more exciting proposition. Playing devils advocate though, PNV was positive EBITDA last quarter- they generate 85-90% margin on their synthetic BTM Novosorb wound product, vs ARX generating 70-76% margin from their sheep foregut product.


What do investors here think about PNV?

My take on sales strategy- in terms of bums on seats, ARX is better positioned to grow, with double PNV US staff. Your growth this year of 80% YoY, PNV isn't going to achieve- if we get a 45 millon dollar year revenue we are sitting on 50-55% YoY growth (still pretty good)